Nanopharmaceutics is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. The pipeline includes 9 clinical-stage proprietary and partnered programs including Triapine®, Ammonium Tetrathiomolybdate and Aza-TdC targeting cancer; NanoBUP™ , PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin™ and NanoDOX™ targeting infectious diseases. The company is also advancing a large, undisclosed portfolio of preclinical development candidates.